A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small cell lung cancer. - eVOLVE-Lung02

Study identifier:D798AC00001

ClinicalTrials.gov identifier:NCT05984277

EudraCT identifier:2023-000056-38

CTIS identifier:2023-503298-39

Recruiting

Official Title

A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC).

Medical condition

metastatic non-small cell lung cancer

Phase

Phase 3

Healthy volunteers

No

Study drug

Volrustomig, Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed

Sex

All

Estimated Enrollment

900

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 24 Oct 2023
Estimated Primary Completion Date: 30 May 2028
Estimated Study Completion Date: 16 May 2029

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria